SeaStar Medical
Update in progressICU (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
SeaStar Medical Holding Corporation is a commercial-stage healthcare company focused on reducing hyperinflammation’s impact on vital organs in the United States. It offers the selective cytopheretic device (SCD), a disease-modifying device that dampens overactive immune cells and the cytokine storm. QUELIMMUNE treats pediatric acute kidney injury due to sepsis; NEUTRALIZE-AKI targets adult AKI in clinical trials. Plans span cardiorenal and hepatorenal syndromes and related conditions. Founded 2007, Denver.
Company score
- Sentiment
- 0.09
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.01
- Governance
- -0.16
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.03
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMr. Eric Schlorff
- Founded2007
- Employees18
- Websiteseastarmedical.com
Identifiers
- ISINUS5020152097
- FIGIBBG00YVJVRK3
- CUSIP81256L203
- CIK0001831868